{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135478","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.611420+00:00","generated_at":"2026-06-02T03:33:47.324261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soleno Q1 net loss $21.4M; FDA breakthrough therapy for DCCR; NDA mid-2024","bullets":["Net loss of $21.4M ($0.59 per share) vs $8.4M loss in Q1 2023; R&D expense rose to $14.6M from $5.3M.","Pro forma cash reserves $307.2M after May 2024 public offering netting $148.8M.","FDA granted Breakthrough Therapy Designation for DCCR in Prader-Willi syndrome; NDA submission on track for mid-2024.","Strengthened leadership: appointed Chief Commercial Officer, VP Europe, VP Human Resources.","Contingent consideration liability for DCCR commercial milestones valued at $12.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135478","json":"https://secwatch.observer/filing/0001193125-24-135478.json","markdown":"https://secwatch.observer/filing/0001193125-24-135478.md","text":"https://secwatch.observer/filing/0001193125-24-135478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/0001193125-24-135478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/d767565d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:33:47.324261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"289ca668a5c51f0c0656c9fb562c48f5e7f578c1","claim":"SOLENO THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, EPS $0.59 per basic and diluted share.","evidence_excerpt":"Net loss was approximately $21.4 million, or $0.59 per basic and diluted share, for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/0001193125-24-135478-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was approximately $21.4 million, or $0.59 per basic and diluted share"},{"label":"EPS","value":"$0.59 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}